Syracuse, NY 的 非小細胞肺癌 臨床試驗
15 項針對 非小細胞肺癌 的研究正在 Syracuse（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
招募中3 期
- Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse · 距離 4 英里
- Hematology Oncology Associates of CNY at Camillus, Camillus · 距離 8 英里
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- State University of New York Upstate Medical University, Syracuse
- SUNY Upstate Medical Center-Community Campus, Syracuse
- Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse · 距離 4 英里
- 還有 1 項
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
招募中2 期
- State University of New York Upstate Medical University, Syracuse
- Upstate Cancer Center at Hill Radiation Oncology, Syracuse
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
招募中3 期
- SUNY Upstate Cancer Center ( Site 0140), Syracuse
- Hematology-Oncology Associates of CNY ( Site 0164), East Syracuse · 距離 4 英里
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #76, Syracuse
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
招募中3 期
- Research Site, East Syracuse · 距離 4 英里
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Hematology-Oncology Associates of CNY, East Syracuse · 距離 4 英里
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
招募中3 期
- SUNY Upstate Medical University, Syracuse
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
招募中3 期
- Research Site, East Syracuse · 距離 4 英里
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
招募中3 期
- Clinical Study Site, Syracuse
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
招募中3 期
- SUNY Upstate Medical University, Syracuse
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
招募中3 期
- Research Site, East Syracuse · 距離 4 英里
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
招募中3 期
- State University of New York Upstate Medical University, Syracuse
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
招募中3 期
- SUNY - Upsate Medical Centre, Syracuse
GEMINI-NSCLC: NSCLC Biomarker Study
招募中觀察性研究
- Hematology Oncology Associates of Central New York, East Syracuse · 距離 4 英里
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Syracuse 的其他研究
- 癌症（所有類型）9 項研究
- 前列腺癌9 項研究
- 非肌層浸潤性膀胱癌8 項研究
- 卵巢癌7 項研究
- 子宮內膜癌7 項研究
- 肥胖症6 項研究
- 肺癌6 項研究
- 大腸直腸癌5 項研究
- 黃斑部病變5 項研究
- 急性髓系白血病5 項研究
- 第二型糖尿病5 項研究
- 紅斑性狼瘡5 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。